Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback